Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
South Africa
0
Listed Dossiers
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 9350, Gs
2. Gs 9350
3. Gs-9350
4. Gs9350
5. Tybost
1. 1004316-88-4
2. Cobicistat (gs-9350)
3. Gs-9350
4. Tybost
5. Gs 9350
6. Cobicistat,gs-9350
7. Unii-lw2e03m5pg
8. Chebi:72291
9. Lw2e03m5pg
10. 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate
11. 1,3-thiazol-5-ylmethyl N-[(2r,5r)-5-[[(2s)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
12. Thiazol-5-ylmethyl ((2r,5r)-5-((s)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-yl)carbamate
13. 1,3-thiazol-5-ylmethyl N-[(2r,5r)-5-[(2s)-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}-4-(morpholin-4-yl)butanamido]-1,6-diphenylhexan-2-yl]carbamate
14. 2,7,10,12-tetraazatridecanoic Acid, 12-methyl-13-(2-(1-methylethyl)-4-thiazolyl)-9-(2-(4-morpholinyl)ethyl)-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl Ester, (3r,6r,9s)-
15. Cobicistat [usan]
16. Cobicistat [usan:inn]
17. Cobicistatum
18. 2,7,10,12-tetraazatridecanoic Acid, 12-methyl-13-[2-(1-methylethyl)-4-thiazolyl]-9-[2-(4-morpholinyl)ethyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl Ester, (3r,6r,9s)-
19. Thiazol-5-ylmethyl (2r,5r)-5-((s)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido)-4-morpholinobutanamido)-1,6-diphenylhexan-2-ylcarbamate
20. Tybost (tn)
21. Cobicistat [mi]
22. Cobicistat [inn]
23. Cobicistat [jan]
24. Cobicistat; Gs-9350
25. Cobicistat [vandf]
26. Cobicistat [who-dd]
27. Cobicistat On Silicon Dioxide
28. Cobicistat (jan/usan/inn)
29. Gtpl7535
30. Schembl2736227
31. Chembl2095208
32. Cobicistat [orange Book]
33. Cobicistat, (r,r,s)-
34. Dtxsid00143269
35. Evotaz Component Cobicistat
36. Genvoya Component Cobicistat
37. Symtuza Component Cobicistat
38. Bcp06630
39. Ex-a2578
40. Rezolsta Component Cobicistat
41. Stribild Component Cobicistat
42. Bdbm50447471
43. Mfcd18251449
44. Prezcobix Component Cobicistat
45. S2900
46. Zinc85537014
47. Cobicistat Component Of Evotaz
48. Akos025404908
49. Cobicistat Component Of Genvoya
50. Cobicistat Component Of Symtuza
51. Ccg-270459
52. Cobicistat Component Of Stribild
53. Cs-0742
54. Db09065
55. Cobicistat Component Of Prezcobix
56. Ncgc00386235-04
57. Ncgc00386235-06
58. Ac-28961
59. As-17061
60. Hy-10493
61. Sw219553-1
62. D09881
63. Ab01566899_01
64. Q5138908
65. (1,3-thiazol-5-yl)methyl (5s,8r,11r)-8,11-dibenzyl-2-methyl-5-(2-(morpholin-4-yl)ethyl)-1-(2-(propan-2-yl)-1,3-thiazol-4-yl)-3,6-dioxo-2,4,7,12-tetraazatridecan-13-oate
66. 1,3-thiazol-5-ylmethyl ((2r,5r)-5-(((2s)-2-((methyl((2-(propan-2-yl)-1,3-thiazol-4-yl)methyl)carbamoyl)amino)-4-(morpholin-4-yl)butanoyl)amino)-1,6-diphenylhexan-2-yl)carbamate
67. Thiazol-5-ylmethyl ((1r,4r)-1-benzyl-4-({(2s)-2-((methyl{(2-(1-methylethyl)thiazol-4-yl)methyl}carbamoyl)amino)-4-(morpholin-4-yl)butanoyl}amino)-5-phenylpentyl)carbamate
68. Thiazol-5-ylmethyl N-[(1r,4r)-1-benzyl-4-[[(2s)-2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-4-morpholino-butanoyl]amino]-5-phenyl-pentyl]carbamate
| Molecular Weight | 776.0 g/mol |
|---|---|
| Molecular Formula | C40H53N7O5S2 |
| XLogP3 | 5.7 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 20 |
| Exact Mass | 775.35496016 g/mol |
| Monoisotopic Mass | 775.35496016 g/mol |
| Topological Polar Surface Area | 195 Ų |
| Heavy Atom Count | 54 |
| Formal Charge | 0 |
| Complexity | 1120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
FDA Label
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older:
- weighing at least 35 kg coadministered with atazanavir or
- weighing at least 40 kg coadministered with darunavir.
Anti-HIV Agents
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)
Cytochrome P-450 CYP3A Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)
V03AX03
J05AR14
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AX - Other therapeutic products
V03AX03 - Cobicistat
Absorption
Median peak plasma concentrations were observed at 3.5 hours post-dose.
Route of Elimination
With single dose administration of [14C] cobicistat after multiple dosing of cobicistat for six days, the mean percent of the administered dose excreted in feces and urine was 86.2% and 8.2%, respectively.
Cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6 enzymes and does not undergo glucuronidation.
The terminal plasma half-life of cobicistat is approximately 3 to 4 hours.
Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-HIV activity on its own.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2016-10-21
Pay. Date : 2016-08-16
DMF Number : 30287
Submission : 2016-09-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25188
Submission : 2011-10-24
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-03-16
Pay. Date : 2018-01-05
DMF Number : 30650
Submission : 2016-07-02
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-10-20
Pay. Date : 2014-07-28
DMF Number : 28438
Submission : 2014-08-08
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2015-10-14
Pay. Date : 2015-08-31
DMF Number : 29615
Submission : 2015-09-02
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Cobicistat on colloidal silicon dioxide IH
Date of Issue : 2025-09-03
Valid Till : 2028-09-02
Written Confirmation Number : WC-0362
Address of the Firm : Plot No:4, Hetero Infrastructure SEZ Ltd.,Narasapuram, Visakhapatnam-531081, And...
Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...

Cobicistat on Silicondioxide IH
Date of Issue : 2023-05-10
Valid Till : 2026-05-10
Written Confirmation Number : WC-0015
Address of the Firm : Unit-8, G.Chodavaram village, Pusapatirega Mandal, Vizianagaram District-535204,...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
NDC Package Code : 69037-0025
Start Marketing Date : 2015-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57572-0035
Start Marketing Date : 2012-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 69766-011
Start Marketing Date : 2016-05-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65015-867
Start Marketing Date : 2015-02-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65015-849
Start Marketing Date : 2015-03-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66721-500
Start Marketing Date : 2012-09-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 84206-0024
Start Marketing Date : 2024-08-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 84206-0025
Start Marketing Date : 2024-08-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The financing aims to fund the clinical development of FORE8394 (plixorafenib), which is being evaluated on mid-stage trial studies for the treatment of BRAF V600-mutated Neoplasms.
Lead Product(s): Plixorafenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: SR One
Deal Size: $113.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Plixorafenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : SR One
Deal Size : $113.0 million
Deal Type : Series D Financing
FORE Biotherapeutics Raises $38M Series D-2 to Advance Plixorafenib
Details : The financing aims to fund the clinical development of FORE8394 (plixorafenib), which is being evaluated on mid-stage trial studies for the treatment of BRAF V600-mutated Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Symtuza-Generic (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) is an FDC product which is indicated for the treatment of HIV-1 infection in adults and pediatric patients.
Lead Product(s): Darunavir,Cobicistat,Emtricitabine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Symtuza-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darunavir,Cobicistat,Emtricitabine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Tentative FDA Approval for Generic Darunavir Combination Tablets
Details : Symtuza-Generic (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) is an FDC product which is indicated for the treatment of HIV-1 infection in adults and pediatric patients.
Product Name : Symtuza-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Revuforj (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Revuforj
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Syndax Reports Positive Data for Revuforj® in Relapsed/Refractory mNPM1 AML
Details : Revuforj (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Product Name : Revuforj
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Revuforj (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Syndax's Blood Cancer Drug
Details : Revuforj (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 15, 2024

Details:
Plixorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Plixorafenib,Cobicistat
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Fore Biotherapeutics | Ivy Brain Tumor Foundation
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2024

Lead Product(s) : Plixorafenib,Cobicistat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Fore Biotherapeutics | Ivy Brain Tumor Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
Details : Plixorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Syndax Announces PDUFA Action Date Extension for Revumenib NDA in KMT2Ar Acute Leukemia
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed/refractory KMT2A-rearranged (KMT2Ar) acute leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Filed a sNDA with the USFDA seeking expanded approval for the use of its HIV-1 therapy, PREZCOBIX (darunavir/cobicistat), in children aged six years and above, weighing at least 25kg.
Lead Product(s): Darunavir,Cobicistat
Therapeutic Area: Infections and Infectious Diseases Brand Name: Prezcobix
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Darunavir,Cobicistat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
J&J seeks expanded approvals for paediatric HIV-1 therapy
Details : Filed a sNDA with the USFDA seeking expanded approval for the use of its HIV-1 therapy, PREZCOBIX (darunavir/cobicistat), in children aged six years and above, weighing at least 25kg.
Product Name : Prezcobix
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Plixorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Plixorafenib,Cobicistat
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 25, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Plixorafenib,Cobicistat
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Plixorafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory mNPM1 Acute Myeloid Leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Syndax Completes Enrollment in AUGMENT-101 Trial of Relapsed/Refractory AML
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of Relapsed/Refractory mNPM1 Acute Myeloid Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia.
Lead Product(s): Revumenib,Cobicistat
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Revumenib,Cobicistat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Syndax Announces FDA Priority Review of NDA for Revumenib in R/R Acute Leukemia
Details : SNDX-5613 (revumenib) is a highly selective, first-in-class oral menin inhibitor, for the treatment of adult and pediatric patients with relapsed or refractory KMT2A-rearranged acute leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results](2R,5R)-1,6-Diphenylhexane-2,5-Diamine Dihydrochlo...
CAS Number : 1247119-31-8
End Use API : Cobicistat
About The Company : Arde’s Laboratories Pvt Ltd. is a specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic pharmaceutical dru...

CAS Number : 38585-74-9
End Use API : Cobicistat
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

5-Hydroxymethyl thiazole
CAS Number : 38585-74-9
End Use API : Cobicistat
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

2- Isopropyl-4-methylaminomethyl thiazole Hydrochl...
CAS Number : 154212-60-9
End Use API : Cobicistat
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

H-Dab (Boc)-OMe Hydrochloride
CAS Number : 3350-15-0
End Use API : Cobicistat
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

3- [[(1,1-Dimethylethoxy)carbonyl]amino]-L-alanine...
CAS Number : 77087-60-6
End Use API : Cobicistat
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

1-(2-isopropylthiazol-4-yl-N-MethylMethanaMine
CAS Number : 1185167-55-8
End Use API : Cobicistat
About The Company : Nanjing Clasien Pharmaceutical & Chemical Co., Ltd. is a high-tech enterprise located in Nanjing, the provincial capital of Jiangsu Province, with excellent loc...

(2R,5R)-1,6-diphenylhexane-2,5-diamine dihydrochlo...
CAS Number : 1247119-31-8
End Use API : Cobicistat
About The Company : Ningbo Chemgoo is a R&D-driven company with core technology of organic chemistry, dedicating in technology development and industrialization. We provide interme...

thiazol-5-ylmethyl (2R,5R)-5-amino-1,6-diphenylhex...
CAS Number : 1247119-33-0
End Use API : Cobicistat
About The Company : Ningbo Chemgoo is a R&D-driven company with core technology of organic chemistry, dedicating in technology development and industrialization. We provide interme...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
49
PharmaCompass offers a list of Cobicistat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cobicistat manufacturer or Cobicistat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cobicistat manufacturer or Cobicistat supplier.
PharmaCompass also assists you with knowing the Cobicistat API Price utilized in the formulation of products. Cobicistat API Price is not always fixed or binding as the Cobicistat Price is obtained through a variety of data sources. The Cobicistat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cobicistat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cobicistat, including repackagers and relabelers. The FDA regulates Cobicistat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cobicistat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cobicistat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cobicistat supplier is an individual or a company that provides Cobicistat active pharmaceutical ingredient (API) or Cobicistat finished formulations upon request. The Cobicistat suppliers may include Cobicistat API manufacturers, exporters, distributors and traders.
click here to find a list of Cobicistat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cobicistat DMF (Drug Master File) is a document detailing the whole manufacturing process of Cobicistat active pharmaceutical ingredient (API) in detail. Different forms of Cobicistat DMFs exist exist since differing nations have different regulations, such as Cobicistat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cobicistat DMF submitted to regulatory agencies in the US is known as a USDMF. Cobicistat USDMF includes data on Cobicistat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cobicistat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cobicistat suppliers with USDMF on PharmaCompass.
A Cobicistat written confirmation (Cobicistat WC) is an official document issued by a regulatory agency to a Cobicistat manufacturer, verifying that the manufacturing facility of a Cobicistat active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cobicistat APIs or Cobicistat finished pharmaceutical products to another nation, regulatory agencies frequently require a Cobicistat WC (written confirmation) as part of the regulatory process.
click here to find a list of Cobicistat suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cobicistat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cobicistat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cobicistat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cobicistat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cobicistat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cobicistat suppliers with NDC on PharmaCompass.
Cobicistat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cobicistat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cobicistat GMP manufacturer or Cobicistat GMP API supplier for your needs.
A Cobicistat CoA (Certificate of Analysis) is a formal document that attests to Cobicistat's compliance with Cobicistat specifications and serves as a tool for batch-level quality control.
Cobicistat CoA mostly includes findings from lab analyses of a specific batch. For each Cobicistat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cobicistat may be tested according to a variety of international standards, such as European Pharmacopoeia (Cobicistat EP), Cobicistat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cobicistat USP).